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ABSTRACT Integrase (IN) is one of the three human immunodeﬁciency virus type 1 (HIV-1) enzymes essential for effective viral
replication. Recently, mutation studies have been reported that have shown that a certain degree of viral resistance to diketo acids
(DKAs) appears when some amino acid residues of the IN active site aremutated. Mutations represent a fascinating experimental
challenge, and we invite theoretical simulations for the disclosure of still unexplored features of enzyme reactions. The aim of this
work is to understand themolecular mechanisms of HIV-1 IN drug resistance, which will be useful for designing anti-HIV inhibitors
with unique resistance proﬁles. In this study, we use molecular dynamics simulations, within the hybrid quantum mechanics/
molecular mechanics (QM/MM) approach, to determine the protein-ligand interaction energy for wild-type and N155S mutant
HIV-1 IN, both complexed with a DKA. This hybrid methodology has the advantage of the inclusion of quantum effects such as
ligand polarization upon binding, which can be very important when highly polarizable groups are embedded in anisotropic
environments, for example in metal-containing active sites. Furthermore, an energy terms decomposition analysis was performed
to determine contributions of individual residues to the enzyme-inhibitor interactions. The results reveal that there is a strong
interaction between the Lys-159, Lys-156, and Asn-155 residues and Mg21 cation and the DKA inhibitor. Our calculations show
that the binding energy is higher in wild-type than in theN155Smutant, in accordance with the experimental results. The role of the
mutated residue has thus been checked as maintaining the structure of the ternary complex formed by the protein, the Mg21
cation, and the inhibitor. These results might be useful to design compounds with more interesting anti-HIV-1 IN activity on the
basis of its three-dimensional structure.
INTRODUCTION
Human immunodeﬁciency virus type 1 (HIV-1) integrase (IN)
is an attractive target for the development of anti-AIDS (auto-
immune deﬁciency syndrome) drugs (1–5). It catalyzes the
integration of double-stranded viral DNA into the host cell’s
genomic DNA (2,3). The integration reaction requires three
biochemical steps: assembly of a stable preintegration complex
at the termini of the viral DNA and two sequential tran-
sesteriﬁcation reactions (2,3). Both reactions consist of a nucle-
ophilic attack of a hydroxyl group on a phosphodiester bond
with the participation of a divalent metal ion (Mg21 or Mn21)
as cofactor (1). The catalytic core domain comprises the amino
acids 50–212, and it contains the conserved DDE motif
(D64, D116, and E152). The mutation of any of these three
amino acid residues inhibits enzyme’s activity (1,5).
A great number of compounds bearing a b-diketo acid
motif (DKAs) with anti-HIV-1 IN activity have been re-
ported (5–8). These compounds represent one of the most
promising classes of IN inhibitors in terms of potency and
selectivity (7), L-731,988 and S-1360 being two of the most
promising ones (8). Recently, one DKA analog (5CITEP), a
well-known bioisoester (9), has been crystallized with the
enzyme (Protein Data Bank (PDB) code 1QS4) (6). In this
x-ray structure, a single Mg21 ion is chelated by Asp-64,
Asp-116, and water molecules in an octahedral coordination.
Computational studies have been performed on DKA com-
pounds by means of classical molecular dynamics (MD)
(10,11) and docking (12–22) studies. In particular, 5-CITEP
and L-731,988 inhibitors have been investigated by quantum
chemical calculations (23) and by classical MD simulation of
a full-length HIV-1 IN dimer complexed with viral DNA
(24). Nevertheless, understanding the molecular mechanism
is far from complete.
Recently, mutation studies have been reported (25–28)
and have shown that a certain degree of viral resistance to
DKAs appears when some amino acid residues of the IN
active site are mutated. In this sense, Hazuda and co-workers
have provided evidence that L-870,810 and DKA inhibitors
(Scheme 1) exhibit discordant sensitivity to resistant muta-
tions (25). However, they showed that in HIV-1 IN only the
mutation of Asn-155 by serine (N155S) confers signiﬁcant
cross-resistance to both inhibitors. In fact, N155S mutation
makes the protein 20- and 12-fold less sensitive to the
L-870,810 and diketo acid, respectively. More recently,
Briggs and co-workers (29–32) have performed classical MD
simulations on double mutant enzyme IN T66I/M154I com-
plexed with both 5CITEP and L-731,988 inhibitors. These
studies suggest that the conformational changes in the loop
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138–149 are responsible for the mechanism of inhibitor
resistance in HIV-1 IN.
Searching for adequate mutations remains a fascinating
experimental challenge, and we invite others to perform the-
oretical simulations to disclose unexplored features of en-
zyme reactions. The aim of this work is to understand the
molecular mechanisms of HIV-1 IN drug resistance, which
will be useful for designing anti-HIV inhibitors with unique
resistance proﬁles. In this work, we employed a combined
quantum mechanical/molecular mechanical (QM/MM) ap-
proach to determine the protein-ligand interaction energy for
wild-type and N155S HIV-1 IN mutant, both complexed
with a DKA (Scheme 1). A detailed analysis of the interac-
tions of each inhibitor with the key residues inside the binding
pocket are carried out from the computational simulations.
The consideration of protein ﬂexibility may be indispens-
able for a critical evaluation of ligand-binding afﬁnity (33–
36). Usually, docking techniques ignore the ﬂexibility of the
receptor, and only the ligand is allowed to suffer conforma-
tional changes during the docking procedure. This limitation
can be partially overcome considering several receptor
structures conveniently picked up from a simulation. How-
ever, cooperative structural changes induced between the
ligand and the receptor are not considered in this strategy. On
the other hand, MD methods can be used to calculate the free
energy of protein/ligand binding, including the ﬂexibility of
the full system (37). The main problem associated with this
methodology is the computational effort required to ade-
quately sample the full conﬁgurational space and also to
parameterize each new ligand essayed. Here we investigate a
strategy to overcome these two computational bottlenecks
based on the use of combined QM/MM methods (38–40).
These methods are now widely used for the analysis of
enzymatic reactions (41,42). In hybrid QM/MM methods,
the ligand/substrate species may be described by a QM
model, whereas the protein and solvent environment is
represented by MM force ﬁelds. This hybrid methodology
avoids most of the work needed to obtain new force ﬁeld
parameters for each new species. Treating the ligand quan-
tum mechanically and the protein molecular mechanically
has the additional advantage of the inclusion of quantum
effects, such as ligand polarization upon binding (43,44).
Moreover, as the largest part of the system is described
classically, enough sampling can be obtained at reasonable
computational cost. There are some recent computational
studies that successfully applied the combined QM/MM
method to the study of protein-ligand interactions in the
HIV-1 protease system (45), the trypsin system (46), and
cyclin-dependent kinase 2 (47). More recently, we success-
fully used this methodology to study the relationship be-
tween protein-ligand interaction energies and anti-HIV-1 IN
activity (48).
METHODS
Model
The initial structure was built from the A-chain of the x-ray crystal structure
complexed with the 5CITEP inhibitor (PDB 1QS4; (6)). This chain was used
as a starting point for our calculations; we changed only the substrate
molecule by the diketo acid depicted in Scheme 1. The Asn-155 residue was
replaced by serine in N155S mutant HIV-1 IN. All the missing residues
(141–144) were added using the HYPERCHEM facility (49). Hydrogen
atoms were placed in the protein according to the predicted pKa of the amino
acids at pH 7. For this purpose, a statistical treatment of electrostatic
potential calculations was performed, as implemented by Field and co-
workers. (See Antosiewicz et al. (50)—where the method is explained and
its accuracy compared with that obtained with other methods—and Gilson
(51).) In this case, no unusual ionization states were found. The carboxylic
group of the inhibitor is deprotonated in water because of its low pKa value,
and consequently it has been modeled in a deprotonated form (9).
QM/MM MD simulations
After adding the hydrogens to the structure, a series of optimization algo-
rithms (steepest descent, conjugated gradient, and LBFGSB) were applied.
To avoid a denaturalization of the protein structure, all the heavy atoms of
the protein and the inhibitor were restrained by means of a Cartesian har-
monic umbrella with a force constant of 1000 kJ mol1 A˚2. Afterward, the
system was fully relaxed, with the exception of restraining the peptidic
backbone with a lower constant (100 kJ mol1 A˚2). After this procedure,
the positions of the initially missing atoms (hydrogen atoms) are optimized,
avoiding large distortions of the protein that could invalidate the following
simulations. The optimized protein was placed in a cubic box (80 A˚ sides) of
preequilibrated waters, using the principal axis of the protein-inhibitor com-
plex as the geometrical center (Fig. 1). Any water with an oxygen atom lying
within a radius of 2.8 A˚ from a heavy atom of the protein was deleted. The
remaining water molecules were then relaxed using optimization algorithms.
Finally, 50 ps of hybrid QM/MM Langevin-Verlet MD (canonical or NVT
ensemble) at 300 K was used to equilibrate the model. For the hybrid QM/
MM calculations, only the atoms of the inhibitor were selected for QM
analysis, using a semiempirical Austin Model 1 (AM1) Hamiltonian (52).
The rest of the system (protein plus water molecules) was described using
the all atoms OPLS potential (OPLS-AA) (53) and TIP3P (54) force ﬁelds,
as implemented in the DYNAMO (55,56) library.
Due to the number of degrees of freedom, any residue 25 A˚ apart from
any of the atoms of the initial inhibitor was selected to be kept frozen in the
remaining calculations (10,235 mobile atoms). Cutoffs for the nonbonding
interactions were applied using a switching scheme, within a radius ranging
11–13 A˚.
Afterward, each system was equilibrated by means of 900 ps of QM/MM
MD at a temperature of 300 K. The computed root mean-square deviation
for the protein during the last 200 ps renders a value that is always below
0.9 A˚. Furthermore, the root mean square of the temperature along the
SCHEME 1 Structure of the DKA-containing HIV-1 IN inhibitor.
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different equilibration steps was always lower than 2.5 K, and the variation
coefﬁcient of the potential energy during the dynamics simulations was
never higher than 0.3%.
Interaction energy calculations
To obtain the interaction energy between the inhibitor and the solvated
enzymatic system, we must keep in mind the expression of the hybrid QM/
MM potential energy:
where VMMðRMMÞ represents the energy of theMM force ﬁeld; Hˆoðr;RQMÞ is
the in vacuoHamiltonian for the selected QMmethod;Cðr;RQM;RMMÞ is the
polarized wave function due to the presence of an external and ﬂexible
electric ﬁeld, generated by the protein and the solvent molecules; and ﬁnally,
VˆQM=MMðr;RMMÞ and VVWQM=MMðRQM;RMMÞ are the electrostatic and van der
Waals coupling operators between the QM andMM parts (the van der Waals
interaction term does not involve electronic coordinates and thus does not
need to be evaluated in the self-consistent ﬁeld (SCF) procedure). The
interaction energy can be then calculated from the analysis of the MD
trajectories as the energy difference between the full QM/MM system and the
separated QM and MM subsystems. Taking into account that in nonpolar-
izable force ﬁelds the MM energy exactly cancels out we can write
E
Int
QM=MM ¼ EVdWQM=MMðRQM;RMMÞ1EElecQM=MMðr;RQM;RMMÞ
1EPolQM=MMðr;RQM;RMMÞ; (3)
which means that in vacuo single-point energy calculation must be car-
ried out for given nuclear conﬁgurations of the quantum atoms along the
trajectory, and then this energy must be subtracted from the QM/MM
energy. Note that according to our deﬁnition of the polarization energy (third
term in Eq. 3) as the gas phase energy difference between the polarized and
unpolarized wave functions, this is a positive contribution.
This scheme for obtaining the interaction energy was applied in a
following 100 ps QM/MM MD run at 300 K, using a time step of 1 fs to
solve the equation of motion. In the calculations here, a switched cutoff
region from 11.0 to 13.5 A˚ was used to calculate the nonbonding interaction
energies. The polarized wave functions are conveniently stored during the
MD simulations, whereas the unpolarized wave functions are obtained a
posteriori using saved coordinates of the QM subsystem. Finally, the
decomposition of the interaction energy term among the different residues of
the protein was carried out using the polarized wave function. For this
purpose we evaluated the interaction of the polarized system with the MM
centers belonging to a particular residue. This procedure provides only the
electrostatic and Lenard-Jones contribution to the interaction energy of a
given residue. Thus, the global polarization energy must be derived from the
difference between the total interaction energy and the sum of the local
contribution of each residue. As stated before, this term is always positive.
The described computational procedure was applied for the investigated
wild-type and N155S mutant complexed with the diketo acid inhibitor.
DFT(B3LYP)/MM calculations
To check the reliability of the structures and the interaction energy calculations
by residue obtained by means of AM1/MM methods, potential energy opti-
mizations were also carried out using density functional theory (DFT) to describe
the quantum region in the hybrid QM/MM scheme. The B3LYP function
(57,58) was employed together with the 6-31G* basis set to describe the QM
region of the system, which includes all atoms of the ligand and the Mg21 ion,
whereas the OPLS-AA force ﬁeld was used for the MM part. This strategy has
been used by Guo et al. (59) to study the stability of the metal ligand bonds.
The potential energy of our scheme is derived from the standard QM/MM
formulation:
E ¼ ÆCjHˆojCæ1

C
 qMMre;MM
C

1++
ZQM qMM
rQM;MM
 
1EvdWQM=MM1EMM (4)
E ¼ EQM1E electQM=MM1EvdWQM=MM1EMMM; (5)
where EMM is the energy of the MM subsystem terms, E
vdW
QM=MM is the van der
Waals interaction energy between the QM andMM subsystems and includes
both the coulombic interaction of the QM nuclei (ZQM) and the electrostatic
interaction of the polarized electronic wave function (C) with the charges of
the protein (qMM), and EQM is the gas phase energy of the polarized wave
function. To take advantage of powerful optimizations algorithms (see Marti
et al. (60)), we substituted the electrostatic interaction term by a pure
coulombic one in which the charges of the QM atoms are obtained by means
of electrostatic potential ﬁt methods based on the electronic density (61).
Thus the ﬁnal potential energy can be approximated by
E ¼ ÆCjHˆojCæ1++
q
ChelpG-fit
QM qMM
rQM;MM
1EvdWQM=MM1EMM: (6)
Finally, the interaction energy between the inhibitor and the environment
is evaluated as the difference between the QM/MM energy and the energies
of the separated, noninteracting QM and MM subsystems with the same
geometry. Considering that the MM part is described using a nonpolarizable
potential, the interaction energy is given by the following expression:
E
Int
QM=MM ¼ ÆCjHˆojCæ ÆCojHˆojCoæ1++
q
ChelpG-fit
QM qMM
rQM;MM
1EvdWQM=MM; (7)
where Co is the gas phase wave function of the inhibitor.
E ¼ VMMðRMMÞ1 ÆCðr;RQM;RMMÞjHˆoðr;RQMÞjCðr;RQM;RMMÞæ
1 ÆCðr;RQM;RMMÞjVˆQM=MMðr;RMMÞjCðr;RQM;RMMÞæ1VVWQM=MMðRQM;RMMÞ; (1)
E
Int
QM=MM ¼ E E0ðRQMÞ  EMMðRMMÞ ¼ EVdWQM=MMðRQM;RMMÞ1 ÆCðr;RQM;RMMÞjVˆQM=MMðr;RMMÞjCðr;RQM;RMMÞæ
1 ÆCðr;RQM;RMMÞjHˆoðr;RQMÞjCðr;RQM;RMMÞæ ÆCoðr;RQMÞjHˆoðr;RQMÞjCoðr;RQMÞæ (2)
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RESULTS AND DISCUSSION
As explained inMethods, hybrid QM/MMMD simulations of
1.0 ns for wild-type and N155S mutant HIV-1 IN complexed
with DKA (Scheme 1) were performed. Table 1 shows the
values of ligand-protein interaction energies for these systems
as well as the ligand-protein interaction energies’ decomposi-
tion into the electrostatic and polarization energy terms. The
reported values are averaged over 100,000 conﬁgurations
from the last 100 ps of the QM/MM MD simulations. Both
geometrical data and energy terms were averaged during the
production run, and the standard deviation is provided in
parenthesis accompanying the average value. The ﬁnal struc-
tures obtained from the 1.0 ns MD simulations are depicted in
Fig. 2,a andb, and the contribution of individual residues to the
total interaction energy is displayed in Fig. 3, a–c. In the latter
ﬁgure, negative values correspond to stabilizing effects. At this
point, it must be noted that the analysis of binding afﬁnity is
done based on ligand-protein interaction energies (electrostatic
and van der Waals). Other possible steric effects or more
complex cooperative effects were not considered in this ap-
proach although, to some extent, change on solvent-substrate
interaction energies uponmutations can be considered indirect
effects. So, experimentally observed free energy changes can
differ from estimations based on interaction energies, but the
purpose here is to ﬁnd the possible origin of these effects, not
to quantify then.
Due to computer limitations, no hybrid QM/MM MD
simulations were carried out within a DFT Hamiltonian.
Nevertheless, single geometry optimizations at the B3LYP/
6-31G*/MM level were carried out for these compounds,
followed by the corresponding analysis of protein-substrate
interactions. In general, AM1/MM and DFT/MM calcula-
tions render quite similar results, thus conﬁrming the reli-
ability of the former.
Wild-type HIV-1 IN complex
From Fig. 2 a and Table 2 we can observe how the car-
boxylic group interacts, through hydrogen bonds, with the
pocket created by Asn-155, Lys-156, and Lys-159 residues.
These interactions favor the stabilization of the protein-
inhibitor complex as reﬂected in Fig. 3 a. In particular, Asn-
155 interacts with Asp-64 and one of the oxygen atoms of
the carboxylic group of the inhibitor; this interaction appears
to be essential for the maintenance of the structure of the
protein-metal-ligand complex. In fact, Hazuda and co-
workers (25) have suggested that a mutation of Asn-155
could directly affect the interaction with the inhibitors by
disrupting metal binding, in accordance with our results.
Thr-66 does not interact directly with the ligand (Fig. 2 a) but
stabilizes the cavity created by the three aforementioned
residues through a hydrogen bond with Lys-159. Another
residue that seems to be essential for catalysis (5) but does
not participate in substrate binding (as worked out from
Fig. 3 a) is the negatively charged Glu-152 residue. Its role
seems to be similar to Thr-66: it interacts with Lys-156 and
Gln-148 residues, thus stabilizing the cavity structure around
the inhibitor.
Both benzene rings of the inhibitor interact with the Mg21
cation through an electrostatic attraction between the quad-
rupole moment created by the p-electrons of the aromatic
moiety and the Mg21 cation, as previously suggested by
Dougherty (62,63). In fact, we can observe that the ben-
zene rings and the Mg21 cation are close to each other, as
FIGURE 1 Overall view of wild-type HIV-1 IN complexed with a DKA
(in ball and sticks, top) and the full molecular system solvated in a cubic box
of 80 A˚ side (bottom).
TABLE 1 Averaged QM/MM interaction energies in kJ mol1
Interaction energy
(kJ mol1)
Elec
(kJ mol1)
Pol
(kJ mol1)
Wild-type 776.0 (638.6) 813.7 37.7
N155S 738.4 (639.7) 772.9 34.5
Values in parentheses correspond to the standard deviations. The corre-
sponding electrostatic (Elec) and polarization (Pol) terms are also reported
in kJ mol1.
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demonstrated by the averaged distance between the center of
mass of the two benzene rings and the Mg21cation, which
are 5.17 A˚ and 5.60 A˚, respectively. This favorable interac-
tion is reﬂected in Fig. 3 a and may explain the metal-
dependent inhibition by DKAs and DKA-like compounds
(64–66). Correspondingly, the same argument can be used to
explain the electrostatic repulsion observed between nega-
tive Asp-64 and the benzene ring.
These results are compatible with previous experimental
studies. Thus, structure-activity relationship studies show
that the aromatic portion is crucial for potency (64) and
strand-transfer selectivity (65,66). Mutagenesis studies show
that Asn-155 and Lys-159 are critical for IN/DNA binding
(67–69), and photo cross-linking studies (70) suggest that the
conserved adenosine binding in the vicinity of Lys-159 and
Glu-152 and the 59-adenosine overhang should be in contact
with Gln-148.
Finally, as observed in Fig. 2 a and Table 2, there are some
water molecules that interact with the inhibitor, stabilizing
the complex as deduced from Fig. 3 a. In particular, one of
the water molecules, which takes part of the coordination
sphere of the ion Mg21, interacts with the p-electrons of the
central benzene ring. A second water molecule is involved
by hydrogen bonds with the keto motif. A third water mol-
ecule interacts with the enol and Lys-156; and the rest of the
water molecules depicted in Fig. 2 a interact with the car-
boxylic group by hydrogen bonds. McCammon et al. (10)
and Briggs et al. (29–32) have found that water molecules
are important in the stabilization of the L-731,988 and IN
complex, in accordance with our theoretical simulations.
Analysis of the complete protein-ligand structure reveals that
FIGURE 3 Contributions of individual amino acid residues to inhibitor
binding (in kJ mol1) of the wild-type HIV-1 IN (a), its N155S mutant (b),
and interaction energy differences between both (c) obtained by means of the
B3LYP(6-31G*)/MM method. ‘‘Water’’ refers to the effect of all the water
molecules in the active site.
FIGURE 2 Representation of the most important interactions between the
wild-type HIV-1 IN (a) and its N155S mutant (b), both complexed with a
DKA, obtained by means of the B3LYP (6-31G*)/MM method. Ball and
stick representation corresponds to the QM region, and the licorice
represents the MM residues and water molecules.
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this inhibitor adopts an orientation in which it may phys-
ically block the possible interface of the IN-DNA complexes,
in accordance with the model suggested by Pommier and co-
workers (8). In addition, this orientation is similar to the one
adopted by 5CITEP in the crystal structure (6) and recently
reported by us for L-731,988 and other derivatives (48) and
S-1360 (71).
N155S HIV-1 IN mutant complex
The structure of the N155S mutant is similar to wild-type,
but the absence of the interaction with Asn-155 provokes
some changes in the interactions. First of all, the smaller size
of Ser-155 creates a hole in the cavity that allows increasing
the interaction with water molecules. The lack of interaction
established between Ser-155 and Asp-64 causes the non-
favorable interaction between this latter residue and the
inhibitor to decrease, as deduced when comparing Fig. 2 a
with b. However, as a related effect, the Mg21 cation moves
away from the inhibitor, and the interaction with the inhibitor
is diminished. However, the inhibitor remains bound within
the N155S IN active site; this is in accordance with drug-
resistance data reported by Hazuda and co-workers (26). The
analysis of the average distance between the Mg21 cation
and the center of mass of the central benzene ring increases
from 5.17 A˚ in the wild-type to 6.10 A˚ in N155S IN, whereas
the distance between the Mg21 cation and the distal benzene
ring goes from 5.60 A˚ to 5.17 A˚. These changes trigger a loss
of ligand-protein interaction energy by 37.6 kJ/mol (see
Table 1). Therefore, the loss of ligand-protein interaction,
mainly through Ser-155 and the Mg21 cation in N155S IN,
may be responsible for the high resistance to the diketo acid.
In fact, it has been experimentally observed that the N155S
mutant is 20-fold less sensitive for this inhibitor (25).
Obviously, these analyses are done with internal energy cal-
culations and not free energies, which means that only
qualitative results can be obtained; a reduction in binding
afﬁnity by a factor of 20 correspond to a much lower reduc-
tion in binding free energy (;4 kJ/mol). The discrepancy
between both quantities is due, on one hand, to the difﬁ-
culties associated with obtaining well-converged internal
energies and, on the other hand, to the fact that apart from
protein-ligand electrostatic interactions other terms must be
considered. So, we must also keep in mind the large inter-
action of the ligand with the solvation waters (see Fig. 3 c)
and the entropic contributions that could partly cancel the
changes in the internal energy observed upon mutation.
For the results obtained we can observe that the structures
and energies for residues obtained with both AM1/MM and
B3LYP/MM methods are comparable. However, the hydro-
gen-bond interactions established between water molecules
and the inhibitor, obtained with the AM1/MM method, are
weaker than those obtained at the B3LYP/MM level.
To check the robustness of the interactions analyzed pre-
viously, the time evolution of protein-inhibitor interaction
energy obtained along the QM/MM MD simulations was
studied (as shown in the Supplementary Material). The
resulting plot shows no important ﬂuctuations in either of the
two compounds, the wild-type and the N155S mutant, thus
supporting the conclusions obtained from the static interac-
tions analysis.
Three-dimensional molecular
electrostatic potential
Recently, we observed that the charges on some key atoms
are important in quantitative structure-activity relationship
studies of ﬂavonoid compounds with anti-HIV activity (72,73).
In addition, previous QM/MM studies for other inhibitors
conﬁrm this hypothesis (48,71). Therefore, in this work we also
calculated the electronic density with the aim of understand-
ing how structural changes can affect substrate charge
distributions. Fig. 4 displays the three-dimensional molec-
ular electrostatic potential (MEP) surfaces for the DKA
shown in Scheme 1. The MEPs were generated with the
Gauss View program (74) from the B3LYP/MM optimized
structures. These surfaces correspond to the isodensity value
of 0.002 a.u. The nucleophilic regions (negative electronic
potential, in black) can be found around the carboxylic and
keto-enol groups and the benzene ring, whereas the electro-
philic regions (positive electrostatic potential, in light gray)
can be found around the hydrogen and carbon atoms. From
Fig. 4 we can observe a much more intense region of
negative electrostatic potential around the carboxylic group
and benzene ring. We can observe that electron-donating
substituents at the aromatic ring (CH3) increase the region
of negative electrostatic potential at the aromatic ring; and,
therefore, it constitutes a more attractive cation-binding site.
In fact, in previous work (48), we observed that DKA
inhibitors with electron-donating substituents in the aromatic
ring provoke higher values of total ligand-inhibitor interac-
tions, which is related to very high values for anti-HIV
TABLE 2 Averaged distances (in A˚) between key atoms/groups
of the integrase active site of wild-type and the N155S form of
the protein and the ligand
Wild-type N155S
MG-ASP-116 1.883 (0.042) 1.880 (0.041)
MG-ASP-64 1.906 (0.044) 1.916 (0.046)
MG-WAT 2.026 (0.061) 2.022 (0.063)
MG-WAT 2.021 (0.067) 2.026 (0.066)
MG-WAT 2.022 (0.060) 2.044 (0.068)
MG-WAT 2.024 (0.068) 2.026 (0.067)
O1-LYS-159 1.874 (0.170) 2.206 (0.329)
O1-WAT 2.087 (0.285) –
O3-LYS-159 2.269 (0.298) 2.033 (0.286)
O3-ASN-155 1.993 (0.179) –
O3-WAT 2.038 (0.205) 2.015 (0.202)
O12-H15 2.111 (0.129) 2.092 (0.132)
O12-WAT 2.130 (0.252) 2.200 (0.346)
Values in parentheses correspond to the standard deviations.
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activity in cells (75). The charges of the Mg21 ion and ligand
in both the wild-type and N155S complex obtained from the
electrostatic potential (61) (provided in the Supplementary
Material) are almost invariant.
CONCLUSIONS
This work provides insight into the activity of a potential
inhibitor against HIV-1 IN. Hybrid QM/MM MD calcula-
tions were carried out for wild-type and N155S HIV-1 IN
complexed with diketo acid to determine the protein-ligand
interaction energy. As observed in the analysis of individual
interactions, the inﬂuence of Asn-155, Lys-156, and Lys-159
seems to be crucial, with the interaction established between
the inhibitor and the latter being especially important. These
interactions, together with the one established with water
molecules of the cavity created by the protein and the Mg21,
might be responsible for the anti-HIV activity. On the other
hand, the orientation of the inhibitor in both the wild-type
and N155S HIV-1 IN complex is close to the orientation
adopted by 5CITEP in the crystal structure. The structure
found for the N155S mutant was similar to wild-type, but the
absence of the interaction with Asn-155 promoted an impor-
tant loss in the interactions. This may be responsible for the
high resistance observed experimentally in diketo acid.
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